Mass spectrometry-based proteomic analysis of human liver cytochrome(s) P450

Toxicology and Applied Pharmacology

Volumn 267, Issue 1, 2013, Pages 125-136

  Shrivas, Kamlesh ^a   Mindaye, Samuel T ^a   Getie Kebtie, Melkamu ^a   Alterman, Michail A ^a  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

Author keywords

Cytochrome P450 expression; Drug metabolizing enzymes; Human liver microsomes; MALDI mass spectrometry; Pharmacoproteomics; Proteomics

Indexed keywords

AROMATASE; CHOLESTANETRIOL 26 MONOOXYGENASE; CYTOCHROME P450; CYTOCHROME P450 26A1; CYTOCHROME P450 2B; CYTOCHROME P450 2C; CYTOCHROME P450 2D; CYTOCHROME P450 3A; CYTOCHROME P450 4A; CYTOCHROME P450 4B1; MESSENGER RNA; STEROL 14ALPHA DEMETHYLASE;

AMINO ACID SEQUENCE; ARTICLE; CELLULAR DISTRIBUTION; ENZYME ACTIVITY; ETHNICITY; FEMALE; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; IN VITRO STUDY; ISOTOPE DILUTION ASSAY; LIVER MICROSOME; MALE; MASS SPECTROMETRY; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; PROTEOMICS; QUANTITATIVE ANALYSIS; SEX DIFFERENCE;

AMINO ACID SEQUENCE; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; HUMANS; MALE; MASS SPECTROMETRY; MICROSOMES, LIVER; MOLECULAR SEQUENCE DATA; PROTEOMICS;

EID: 84872229815     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2012.12.008     Document Type: Article

References (44)

1. Alterman M.A., Kornilayev B., Duzhak T., Yakovlev D. Quantitative analysis of cytochrome P450 isozymes by means of unique isozyme-specific tryptic peptides: a proteomic approach. Drug Metab. Dispos. 2005, 33:1399-1407.
2. Anderson L., Seilhamer J. A comparison of selected mRNA and protein abundances in human liver. Electrophoresis 1997, 18:533-537.
3. Benk A.S., Roesli C. Label-free quantification using MALDI mass spectrometry: considerations and perspectives. Anal. Bioanal. Chem. 2012, 404:1039-1056.
4. Chen G., Gharib T.G., Huang C.-C., Taylor J.M.G., Misek D.E., Kardia S.L.R., Giordano T.J., Iannettoni M.D., Orringer M.B., Hanash S.M., Beer D.G. Discordant protein and mRNA expression in lung adenocarcinomas. Mol. Cell. Proteomics 2002, 1:304-313.
5. Chinese Human Liver Proteome Profiling Consortium First insight into the human liver proteome from PROTEOMESKY-LIVERHu 1.0, a publicly available database. J. Proteome Res. 2010, 9:79-94.
6. Conrads K.A., Yi M., Simpson K.A., Lucas D.A., Camalier C.E., Yu Li-Rong, Veenstra T.D., Stephens R.M., Conrads T.P., Beck G.R. A combined proteome and microarray investigation of inorganic phosphate-induced pre-osteoblast cells. Mol. Cell. Proteomics 2004, 3:960-969.
7. Cox J., Mann M. Is proteomics the new genomics?. Cell 2007, 130:395-398.
8. Daly A.K. Genetic polymorphisms affecting drug metabolism. Recent advances and clinical aspects. Adv. Pharmacol. 2012, 63:137-167.
9. Davydov D.R. Microsomal monooxygenase as a multienzyme system: the role of P450-P450 interactions. Expert Opin. Drug Metab. Toxicol. 2011, 7:543-558.
10. Eberl H.C., Mann M., Vermeulen M. Quantitative proteomics for epigenetics. ChemBioChem 2011, 12:224-234.
11. Galeva N., Alterman M. Comparison of one-dimensional and two-dimensional gel electrophoresis as a separation tool for proteomic analysis of rat liver microsomes: cytochromes P450 and other membrane proteins. Proteomics 2002, 2:713-722.
12. Getie-Kebtie M., Lazarev A., Eichelberger M., Alterman M. Label-free mass spectrometry-based relative quantification of proteins separated by one-dimensional gel electrophoresis. Anal. Biochem. 2011, 409:202-212.
13. Goldstein J.A. Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br. J. Clin. Pharmacol. 2001, 52:349-355.
14. Griffin T.J., Gygi S.P., Ideker T., Rist B., Eng J., Hood L., Aebersold R. Complementary profiling of gene expression at the transcriptome and proteome levels in Saccharomyces cerevisiae. Mol. Cell. Proteomics 2002, 1:323-333.
15. Guengerich F.P. Cytochromes P450, drugs, and diseases. Mol. Interv. 2003, 3:194-204.
16. Gygi S.P., Rochon Y., Franza B.R., Aebersold R. Correlation between protein and mRNA abundance in yeast. Mol. Cell. Biol. 1999, 19:1720-1730.
17. Huber M., Bahr I., Kratzchmar J.R., Becker A., Mueller E.C., Donner P., Pohlenz H.D., Schneider M.R., Sommer A. Comparison of proteomic and genomic analyses of the human breast cancer cell line T47D and the antiestrogen-resistant derivative T47D-r. Mol. Cell. Proteomics 2004, 3:43-55.
18. Ingelman-Sundberg M. Human drug metabolising cytochrome P450 enzymes: properties and polymorphisms. Naunyn-Schmiedeberg's Arch. Pharmacol. 2004, 369:89-104.
19. Kawakami H., Ohtsuki S., Kamiie J., Suzuki T., Abe T., Terasaki T. Simultaneous absolute quantification of 11 cytochrome P450 isoforms in human liver microsomes by liquid chromatography tandem mass spectrometry with in silico target peptide selection. J. Pharm. Sci. 2011, 100:341-352.
20. Kornilayev B., Alterman M.A. Utility of polyclonal antibodies targeted toward unique tryptic peptides in the proteomic analysis of cytochrome P450 isozymes. Toxicol. in Vitro 2008, 22:779-787.
21. Koskela S., Hakkola J., Hukkanen J., Pelkonen O., Sorri M., Saranen A., Anttila S., Fernandez-Salguero P., Gonzalez F., Raunio H. Expression of CYP2A genes in human liver and extrahepatic tissues. Biochem. Pharmacol. 1999, 57:1407-1413.
22. Krause E., Wenschuh H., Jungblut P.R. The dominance of arginine-containing peptides in MALDI-derived tryptic mass fingerprints of proteins. Anal. Chem. 1999, 71. (4160-41-65).
23. Kuehl P., Zhang J., Lin Y., Lamba J., Assem M., Schuetz J., Watkins P.B., Daly A., Wrighton S.A., Hall S.D., Maurel P., Relling M., Brimer C., Yasuda K., Venkataramanan R., Strom S., Thummel K., Boguski M.S., Schuetz E. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat. Genet. 2001, 27:383-391.
24. Langenfeld E., Zanger U.M., Jung K., Meyer H.E., Marcus K. Mass spectrometry-based absolute quantification of microsomal cytochrome P450 2D6 in human liver. Proteomics 2009, 9:2313-2323.
25. Liao Wei-Li, Heo Gun-Young, Dodder N.G., Reem R.E., Mast N., Huang S., DiPatre P.L., Turko I.V., Pikuleva I.A. Quantification of cholesterol-metabolizing P450s CYP27A1 and CYP46A1 in neural tissues reveals a lack of enzyme-product correlations in human retina but not human brain. J. Proteome Res. 2011, 10:241-248.
26. Lisitsa A.V., Petushkova N.A., Thiele H., Moshkovskii S.A., Zgoda V.G., Karuzina I.I., Chernobrovkin A.L., Skipenko O.G., Archakov A.I. Application of slicing of one-dimensional gels with subsequent slice-by-slice mass spectrometry for the proteomic profiling of human liver cytochromes P450. J. Proteome Res. 2010, 9:95-103.
27. Liu H., Sadygov R.G., Yates J.R. A model for random sampling and estimation of relative protein abundance in shotgun proteomics. Anal. Chem. 2004, 76:4193-4201.
28. Luss H., Li R., Shapiro R., Tzeng E., McGowan F., Yoneyama T., Hatakeyama K., Geller D., Mickle D., Simmons R., Billiar T. Dedifferentiated human ventricular cardiac myocytes express inducible nitric oxide synthase mRNA but not protein in response to IL-1, TNF, IFNgamma, and LPS. J. Mol. Cell. Cardiol. 1997, 29:1153-1165.
29. Maiolica A., Jünger M.A., Ezkurdia I., Aebersold R. Targeted proteome investigation via selected reaction monitoring mass spectrometry. J. Proteomics 2012, 75:3495-3513.
30. Ohtsuki S., Schaefer O., Kawakami H., Inoue T., Liehner S., Saito A., Ishiguro N., Kishimoto W., Ludwig-Schwellinger E., Ebner T., Terasaki T. Simultaneous absolute protein quantification of transporters, cytochromes P450, and UDP-glucuronosyltransferases as a novel approach for the characterization of individual human liver: comparison with mRNA levels and activities. Drug Metab. Dispos. 2012, 40:83-92.
31. Pascal L.E., True L.D., Campbell D.S., Deutsch E.W., Risk M., Coleman I.M., Eichner L.J., Nelson P.S., Liu A.Y. Correlation of mRNA and protein levels: cell type-specific gene expression of cluster designation antigens in the prostate. BMC Genomics 2008, 9:246.
32. Patterson L.H., Murray G.I. Tumour cytochrome P450 and drug activation. Curr. Pharm. Des. 2002, 15:1335-1347.
33. Person M.D., Lo Herng-Hsiang, Towndrow K.M., Jia Z., Monks T.J., Lau S.S. Comparative identification of prostanoid inducible proteins by LC-ESI-MS/MS and MALDI-TOF mass spectrometry. Chem. Res. Toxicol. 2003, 16:757-767.
34. Piana C., Surh L., Furst-Recktenwald S., Iolascon A., Jacqz-Aigrain E.M., Jonker I., Russo R., Van Schaik R.H.N., Wessels J., Della Pasqua O.E. Integration of pharmacogenetics and pharmacogenomics in drug development: implications for regulatory and medical decision making in pediatric diseases. J. Clin. Pharmacol. 2012, 52:704-716.
35. Redlich G., Zanger U.M., Riedmaier S., Bache N., Giessing A.B.M., Eisenacher M., Stephan C., Meyer H.E., Jensen O.N., Marcus K. Distinction between human cytochrome P450 (CYP) isoforms and identification of new phosphorylation sites by mass spectrometry. J. Proteome Res. 2008, 7:4678-4688.
36. Roy J.-N., Lajoie J., Zijenah L.S., Barama A., Poirier C., Ward B.J., Roger M. CYP3A5 genetic polymorphisms in different ethnic populations. Drug Metab. Dispos. 2005, 33:884-887.
37. Seibert C., Davidson B.R., Fuller B.J., Patterson L.H., Griffiths W.J., Wang Y. Multiple-approaches to the identification and quantification of cytochromes P450 in human liver tissue by mass spectrometry. J. Proteome Res. 2009, 8:1672-1681.
38. Stapels M.D., Barofsky D.F. Complementary use of MALDI and ESI for the HPLC-MS/MS analysis of DNA-binding proteins. Anal. Chem. 2004, 76:5423-5430.
39. Su T., Bao Z., Zhang Q.-Y., Smith T.J., Hong J.-Y., Ding X. Human cytochrome P450 2A13: predominant expression in the respiratory tract and its high efficiency metabolic activation of a tobacco-specific carcinogen, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. Cancer Res. 2000, 60:5074-5079.
40. Tian Q., Stepaniants S.B., Mao M., Weng L., Feetham M.C., Doyle M.J., Yi E.C., Dai H., Thorsson V., Eng J., Goodlett D., Berger J.P., Gunter B., Linseley P.S., Stoughton R.B., Aebersold R., Collins S.J., Hanlon W.A., Hood L.E. Integrated genomic and proteomic analyses of gene expression in mammalian cells. Mol. Cell. Proteomics 2004, 3:960-969.
41. Wang M.Z., Wu J.Q., Dennison J.B., Bridges A.S., Hall S.D., Kornbluth S., Tidwell R.R., Smith P.C., Voyksner R.D., Paine M.F., Hall J.E. A gel-free MS-based quantitative proteomic approach accurately measures cytochrome P450 protein concentrations in human liver microsomes. Proteomics 2008, 8:4186-4196.
42. Williamson B.L., Purkayastha S., Hunter C.L., Nuwaysir L., Hill J., Easterwood LaHoma, Hill J. Quantitative protein determination for CYP induction via LC-MS/MS. Proteomics 2011, 11:33-41.
43. Yu Ai-Ming, Qu J., Felmlee M.A., Cao J., Jiang Xi-Ling Quantitation of human cytochrome P450 2D6 protein with immunoblot and mass spectrometry analysis. Drug Metab. Dispos. 2009, 37:170-177.
44. Zanger U.M., Turpeinen M., Klein K., Schwab M. Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation. Anal. Bioanal. Chem. 2008, 392:1093-1108.